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The use of camptothecin (CPT), hyperoside and/ or trifolin in 
preventing or inhibiting the growth of fungal pathogens, 
including molds. 
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Compound (pg/mL) 
Fungus Control CPT Trifolin Hyperoside Maneba Bravoh 
Alternan'a alternata 0 10, 25, 50, 75, 
100, 125, 150 
3,000 10,000 
Epicoccum nigrum 0 10, 25, 50, 75, 
100, 125, 150 
3,000 10,000 
Pestalotia guepinii 0 10, 30, 50, 70, 50, 100, 50,100,150 
100, 125,150 150 
3,000 10,000 
Drechslera sp. 0 10, 30, 50, 70, 50, 100, 50,100,150 
- 100,125,150 150 
3,000 10,000 
Fusarium avenaceum 0 10, 30, 50, 70, 50, 100, 50,100,150 
100, 125,150 150 
3,000 10,000 
a the concentration of active ingredient chlorothalonil. ” the concentration of active ingredient manganous 
ethylenebis[dithiocarbamate]. 
Figure 8 
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ECSO (pg/mL) MIC (pg/mL) 
Fungus CPT Trifolin Hyperoside CPT Trifolin Hyperosidé 
Alteman'a alternata <25 <75 
Epicoccum nigrum <10 <75 
Pestalotia guepinii 10 <50 <50 <125 100-150 100-150 
Drechslera sp. <10 <50 <50 <1 00 ' <100 100-150 
Fusarium avenaceum 10-30 75 75 <125 <125 >150 
Figure 9 
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METHODS FOR INHIBITING FUNGAL 
PATHOGEN INFESTATION AND PROPOGATION 
BACKGROUND OF THE INVENTION 
[0001] 1. Field of The Invention 
[0002] Applicant’s invention generally relates to the ?eld 
of plant pathology. Speci?cally, the proposed invention 
includes compositions, processes for their production, and 
methods for their use in controlling certain plant fungal 
pathogens, including molds. 
[0003] 2. Background Information 
[0004] a. Fungal Infestation 
[0005] Fungal infestations (largely of the subset of 
“molds”) in the plant realm come in a Wide variety of forms 
and they, as Well as, in some cases, the conventional 
measures to combat them, extract an enormous toll, eco 
nomically, aesthetically and environmentally. 
[0006] The mold subset of fungus share the characteristics 
of forming a mycelium, but lacking a sporocarp. Mold 
spores are ubiquitious, germinate quickly and often quickly 
substrates rapidly. 
[0007] In the food realm, (e.g., bread, cheese, peaches) or 
manufactured goods of organic origin, molds represent an 
often serious health haZard. By Way of example, Allernaria, 
Epicoccum, Drechslera, and Fusarium are all objects of 
allergies (sometimes life-threatening allergies) in many 
humans. 
[0008] Agricultural, horticultural and forest plants are also 
threatened by fungal pathogens native to the United States as 
Well as invasive fungi from other countries. Thus, the export 
of agricultural crops from the United States to other coun 
tries is sometimes in?uenced by the presence/absence of 
fungi of importance in relation to plant quarantine regula 
tions. 
[0009] According to the 2003 report of the Agricultural 
Research Service of the US. Department of Agriculture, 
economic loss to agricultural and horticultural crops from 
disease-causing fungi is estimated at $20 billion per year in 
the United States. In addition, fungi often limit U.S. agri 
cultural exports, a signi?cant negative factor for the US. in 
the over-all balance of trade. 
[0010] Currently available, broad-spectrum fungicides are 
mostly synthetic, and are of limited e?icacy and/or are 
environmentally pernicious, e.g., chlorothalonil (Daconil 
Ultrex, Daconil Zn, Daconil Weather Stikiuse of these 
products on home laWns is prohibited), iprodione (Chipco 
260l9iprohibited at residential sites), mancoZeb (Fore), 
maneb, ?xed coppers and Zineb. The most e?‘ective fungi 
cide applications may provide only a 50-60% reduction in 
the above-described diseases. Ironically, application of some 
major herbicides even increased the presence of F usarium in 
crops. 
[0011] Among the fungal disease categories of paramount 
concern to society is that knoWn as “leaf spot.” Leaf spot is 
a common descriptive term applied to a number of Wide 
spread and destructive fungal diseases Which a?cect virtually 
all commonly groWn trees and shrubs. Plant varieties dilfer 
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in their susceptibility to leaf spot, but the primary symptom 
of a leaf spot disease typically comes as broWn spots on 
foliage. 
[0012] Leaf spot diseases are caused by a variety of fungal 
pathogens Which can survive from year to year as spores or 
mycelium (fungal threads) in dead plant debris, in the thatch 
layer, and in infected plant parts. Once into the leaf, the 
fungi continue to groW and leaf tissue is destroyed. Spots 
tend to groW and multiply to the point that they merge to 
become a “blight” or a “blotch.” Partial to complete defo 
liation of the plant may occur under conditions Which are 
favorable for the causal fungus. 
[0013] If to be even partly e?fective, presently available 
fungicides must be applied as a protectant before the fungus 
spore is disseminated to the leaf. Optimal, though incom 
plete control of fungal infestations through use of conven 
tional fungicides usually requires tWo to three spray appli 
cations, With additional applications typically shoWing 
nominal, if any greater e?icacy, and/or e?fecting one or more 
undesirable side e?fects in the plants or surrounding envi 
ronment Which outWeigh any advantages of further use. 
[0014] Root rot is another product of fungal infestation 
and, like leaf spot, arises from several different species of 
fungus that are common to ?eld soil, sand, pond and stream 
Water and their sediments, as Well as in dead roots of 
previous crops. Root rot is typically fatal for the infected 
plants, With earlier symptoms including Wilting, yelloWing 
and retention of dried foliage and darkening of young feeder 
roots and occasionally the larger roots. Root rot is di?icult 
to control once it has begun. 
[0015] Of particular note in the root rot context is 
F usarium, Which is a genus of fungi and a Well-knoWn plant 
pathogen. F usarium Wilt a?fects many di?ferent horticultural 
plants and is the most important pathological problem of 
plants groWn in arti?cial groWing media. Fusarium is a 
?lamentous fungus that is Widely distributed on plants and 
in the soil. Several different species of Fusarium (including 
F oxysporum, F solani, and F avenaceum) can cause root 
rot of, among other things, container tree seedlings. 
[0016] Fusarium root rot is one of the most common 
diseases of seedlings in the World and is Widespread in North 
American nurseries. Most conifer seedlings, including 
spruces, true ?rs, pines and larch are susceptible to 
Fusarium root rot. Fungicidal drenches are commonly used 
in attempts to control F usarium root rot, but these treatments 
function primarily to impede the spread of the infestation, 
and rarely are there any indications of an actual reversal of 
an existing infestation. 
0017 b. Cam lolheca acuminala and cam tothecin P P 
(CPT). 
[0018] Camplolheca acuminala is a member of the family 
Nyssaceae (tupelo family). This fast-groWing, deciduous 
tree is native only to China and Tibet. This tree (along With 
some alternative sources to be discussed beloW) is a source 
for a potent anti-leukemia and anti-tumor ingredientia 
quinoline alkaloid called camptothecin (CPT). CPT has been 
modi?ed to create many other anti-cancer drugs, including 
irinotecan, topotecan, 9-aminocamptothecin, and CPT-ll. 
[0019] CPT and these analogs are being investigated to 
treat a Wide variety of cancers, but the compounds are quite 
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toxic. Only topotecan (Hycamtin®) and irinotecan HCl 
(Camptosar®) have met With FDA approval; Hycamtine® 
has been approved for ovarian cancer therapy, and Camp 
tosar® is approved for metastatic colorectal cancers. 
[0020] Leaf spots caused by Allernaria, Epicoccum, and 
Peslalolia, as Well as root rots caused by Fusarium, are 
major fungal diseases affecting biomass and CPT production 
in Camplolheca cultivation. 
[0021] Leaf spots often increase in severity as the growing 
season progresses and leaves become mature. Leaves die 
and drop off prematurely, and the all-important CPT yields 
are decreased as a result of the diseased plant’s decreased 
ability to carry out photosynthesis. 
[0022] Contributing fungal factors in leaf spot in Camp 
Zolheca include E. nigrum. E. nigrum is a cosmopolitan 
saprophyte found on many plants, textiles, paper products, 
and foodstuff, in soils and air samples. R guepinii is prima 
rily a secondary pathogen. It is saprophytic on dead and 
dying tissues and is Weakly parasitic, infecting through 
Wounds under moist conditions. Drechslera spp. are either 
plant pathogens or saprobes. Fusarium, as previously men 
tioned, is a soil borne fungus With WorldWide distribution, 
particularly throughout tropical and subtropical areas. 
[0023] c. Present Anti-fungal Research and Conventional 
Anti-fungal Measures. 
[0024] Dithiocarbamates are organic fungicides com 
monly used for the treatment of soil, seeds, and foliar and 
postharvest diseases of some crops. Dithiocarbamates, 
including Maneb, N,N-diethyldithiocarbamic acid sodium 
salt, and some neWly synthetic compounds, are shoWn to 
inhibit groWth of F oxysporum f. sp. lini, but only by 7-30% 
at the concentration of 100 ppm (100 ug/mL). 
[0025] As the most potent antifungal compound of the 
essential oils of 13 herbs selected by Sridhar et al. (2003), 
geraniol isolated from cymbopogan (Cymbopogan martini) 
inhibited groWth of Bolrylis cinerea in both in vitro tests and 
TLC bioautography With a minimum concentration of 160 
ug/mL (MIC). Essential oils of Salvia sclarea L. (Lami 
aceae) inhibited groWth of F oxysporum f. sp. dianthi by 
72% at concentrations of 2,000 uL/L. [3-Asarone from 
rhiZomes of Acorus gramineus Solander (Araceae) Was 
effective against mycelial groWth of Allernaria mali (With 
MIC>l00 ug/mL) and F oxysporum f.sp. lycopersici (With 
MIC>l00 ug/mL). Vanillin, 4-hydroxy-3-methoxycinnama 
ldehyde, and (1) pinoresinol isolated from Melia aZedarach 
L. (Meliaceae) controlledF verlicillioides at higher concen 
trations (With MICs of 600, 400, and 1,000 ug/mL, respec 
tively). 
[0026] Despite the limited ef?cacy of the above-described 
anti-fungal agents, and in particular vieW of the dramatic 
increase, in recent times, in pathogen resistance to both 
agrochemical and pharmaceutical fungicides, discovery of 
neW antimicrobial compounds With neW modes of action is 
becoming increasingly important. No presently-available 
fungicide is particularly effective against leaf spots and root 
rots. 
[0027] In vieW of the above, there exists a dire need for, 
not only composition(s) With effective, broad spectrum 
anti-fungal properties, but ones Which are, to the greatest 
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degree possible, environmentally benign. Also needed are 
method(s) to economically produce such agents or compo 
sitions. 
SUMMARY OF THE INVENTION 
[0028] It is an object of the present invention to provide 
compositions for controlling plant fungal pathogens. 
[0029] It is an object of the present invention to provide 
compositions for more effectively controlling plant fungal 
pathogens than is possible through use of presently available 
compositions or methods. 
[0030] It is another object of the present invention to 
provide compositions for controlling plant fungal pathogens, 
Which compositions are more environmentally benign than 
presently-available compositions of similar intended use. 
[0031] It is another object of the present invention to 
provide a method for producing compositions for controlling 
plant fungal pathogens. 
[0032] It is another object of the present invention to 
provide a method for producing compositions for more 
effectively controlling plant fungal pathogens than is pos 
sible through use of presently available compositions or 
methods. 
[0033] It is another object of the present invention to 
provide a method for producing compositions for controlling 
plant fungal pathogens, Which compositions are more envi 
ronmentally benign than presently-available compositions 
of similar intended use. 
[0034] It is another object of the present invention to 
provide a method for controlling plant fungal pathogens 
more effective than is possible through use of presently 
available compositions or methods. 
[0035] It is another object of the present invention to 
provide a method for controlling plant fungal pathogens, 
Which compositions are more environmentally benign than 
are presently-available compositions of similar intended use. 
[0036] It is another object of the present invention to 
provide a method for controlling plant fungal pathogens 
more cost-effective than is possible through use of presently 
available compositions or methods. 
[0037] In satisfaction of these and related objectives, 
Applicant’s present invention provides compositions, meth 
ods for producing compositions, and method of use of such 
compositions Which collectively satisfy all of the above 
objects, and individually meet at least a subset of such 
objects. 
[0038] The present invention relates to camptothecin 
(CPT) and the ?avonoids trifolin and hyperoside, all isolated 
from plants knoWn to contain same. All experimental data 
to-data arises extraction from Camplolheca., hoWever, the 
folloWing plant species are presently also knoWn to contain 
CPT, and extraction from such plants (methods for Which are 
Within the scope of knowledge of persons reasonably skilled 
in chemical extraction methodologies) Will also fall Within 
the scope of the present invention: 
[0039] A. Camplolheca (Nyssaceae); including: Camp 
Zolheca acuminala Decaisne, Camplolheca acuminala 
var. Zenuifolia Fang et Song, Camplolheca acuminala 
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var. rolundifolia Yang et Duan, Camplolheca yunnan 
ensis Dode, Camplolheca lowreyana Li, Camplolheca 







[0045] G. Pyrenacanlha (Icacinaceae). 
[0046] CPT, trifolin and hyperoside all exhibit unprec 
edented control over plant fungal pathogens in a cost 
e?fective and environmentally-safe Way, and the present 
inventors believe that analogues thereof Would perform 
likewise. 
[0047] CPT, trifolin, and hyperoside de?nitely and 
remarkably exhibit antifungal activity in Camplolheca 
plants. In fact, CPT affects cell groWth of almost all organ 
isms because it is a potent inhibitor of DNA topoisomerase. 
[0048] As compared With the above-mentioned N,N-di 
ethyldithiocarbamic acid sodium salt (Which shoWed only a 
7-30% fungal groWth inhibition, at the same concentrations), 
for example, CPT, trifolin, and hyperoside inhibited groWth 
of the related fungal pathogen F avenaceum by 70% in vitro. 
B. Ervalamia (Apocynaceae); 
C. Nolhapodyles (Mappia) (Olacaceae); 
D. Ophiorrhiza (Rubiaceae); 
E. Merrilliodendron (Icacinaceae); 
F. Mosluea (Loganiaceae); 
[0049] The present inventors have effected a CPT-in 
duced, 50% inhibition of mycelial groWth (ECSO) at rela 
tively loW concentrations: approximately 10 ug/mL for E. 
nigrum, R guepinii, and Drechslera sp., <25 ug/mL for A. 
allernala, and <30 ug/mL for F avenaceum (Table 2). 
Higher levels of CPT more effectively inhibited mycelial 
groWth, but the minimal inhibitory concentration varied 
betWeen the fungi: 75 ug/mL for A. allernala and E. nigrum, 
100 ug/mL for Drechslera sp., 125 ug/mL forR guepinii and 
F avenaceum. 
[0050] The ?avonoids Were less effective than the alkaloid 
CPT at the level of 50 ug/mL, particularly during the ?rst 
three Weeks of experimentation, but more effective than the 
alkaloid at the level of 100 or 150 ug/mL during the Whole 
experimental period. 
[0051] CPT, trifolin and hyperoside Were, at all experi 
mental concentrations, highly effective in inhibiting Drech 
slera sp. and F avenaceum, and at relatively higher con 
centrations, CPT Was effective in suppressing groWth of A. 
allernala and E. nigrum. 
[0052] Over-all, the present inventors have effectively 
produced, through use of CPT, trifolin, and hyperoside, a 
higher e?icacy in combating fungal groWth and viability 
than many recently discovered and, prior to the present 
invention, the most highly e?icacious antifungal agents. 
[0053] The present inventors ?nd that CPTs, potent inhibi 
tors of the enzyme DNA Topoisomerase I, has not been 
previously recognized in fungicide development. 
[0054] Trifolin and hyperoside are abundant in Camplolh 
eca and some other plants. Although their mechanisms of 
action against fungi are unclear, their effectiveness, avail 
ability, loW cost, and probable loW toxicity to humans make 
the ?avonoids effective fungicides. 
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[0055] To date, commercial CPT synthesis is not feasible, 
and supplies of CPT required for the manufacture of the 
drugs are noW extracted from the fruits of Camplolheca 
acuminala Decaisne, Which has been listed as an endan 
gered species in China since 1997. 
[0056] Cultivation of the tree in the Us. is limited because 
it groWs in subtropical climates. Moreover, the tree takes 
approximately 10 years to produce a stable fruit yield. 
Fungal diseases, particularly leaf spot and root rots, are a 
main limiting factor in the cultivation of Camplolheca in 
plantations for vegetative biomass and CPT production. 
[0057] On the other hand, potential demands of trifolin 
and hyperoside can be easily met because the source plants 
are commonly availableieven from banana, haWthorns, 
and oaks. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0058] FIG. 1 shoWs the structure of the alkaloid camp 
tothecin (CPT) and the ?avonoids, namely, trifolin and 
hyperoside, isolated from Camplolheca acuminala. 
[0059] FIG. 2 is a graph illustrating the effect of different 
concentrations of camptothecin (CPT) and fungicides Bravo 
and Maneb on mycelial groWth of Allernaria allernala. 
Concentrations of CPT: 10 ug/mL (CPT-10), 25 ug/mL 
(CPT-25), 50 ug/mL (CPT-50), 75 ug/mL (CPT-75), 100 
ug/mL (CPT-100), 125 ug/mL (CPT-125), and 150 ug/mL 
(CPT-150); Concentration of Bravo: 10,000 ug/mL (Bravo); 
Concentration of Maneb: 3,000 ug/mL (Maneb). Points and 
bars represent the means and standard errors of ?ve repli 
cates. 
[0060] FIG. 3 is a graph illustrating the effect of different 
concentrations of camptothecin (CPT) and fungicides Bravo 
and Maneb on mycelial groWth of Epicoccum nigrum. 
Concentrations of CPT: 10 ug/mL (CPT-10), 25 ug/mL 
(CPT-25), 50 ug/mL (CPT-50), 75 ug/mL (CPT-75), 100 
ug/mL (CPT-100), 125 ug/mL (CPT-125), and 150 ug/mL 
(CPT-150); Concentration of Bravo: 10,000 ug/mL (Bravo); 
Concentration of Maneb: 3,000 ug/mL (Maneb). Points and 
bars represent the means and standard errors of ?ve repli 
cates. 
[0061] FIG. 4 is a graph illustrating the effect of different 
concentrations of camptothecin (CPT), trifolin, and hypero 
side and fungicides Bravo and Maneb on mycelial groWth of 
Peslalolia quepinii. Concentrations of CPT: 10 ug/mL (CPT 
10), 30 ug/mL (CPT-30), 50 ug/mL (CPT-50), 70 ug/mL 
(CPT-70), 100 ug/mL (CPT-100), 125 ug/mL (CPT-125), 
and 150 ug/mL (CPT-150); Concentrations of Trifolin: 50 
ug/mL (Trifolin-50), 100 ug/mL (Trifolin-100), and 150 
ug/mL (Trifolin-150); Concentrations of Hyperoside: 50 
ug/mL (Hyperoside-50), 100 ug/mL (Hyperoside-100), and 
150 ug/mL (Hyperoside-150); Concentration of Bravo: 
10,000 ug/mL (Bravo); Concentration of Maneb: 3,000 
ug/mL (Maneb). Points and bars represent the means and 
standard errors of ?ve replicates. 
[0062] FIG. 5 is a graph illustrating the effect of different 
concentrations of camptothecin (CPT), trifolin, and hypero 
side and fungicides Bravo and Maneb on mycelial groWth of 
Drechslera sp. Concentrations of CPT: 10 ug/mL (CPT-10), 
30 ug/mL (CPT-30), 50 ug/mL (CPT-50), 70 ug/mL (CPT 
70), 100 ug/mL (CPT-100), 125 ug/mL (CPT-125), and 150 
ug/mL (CPT-150); Concentrations of Trifolin: 50 ug/mL 
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(Trifolin-50), 100 ug/mL (Trifolin-100), and 150 ug/mL 
(Trifolin-150); Concentrations of Hyperoside: 50 ug/mL 
(Hyperoside-50), 100 ug/mL (Hyperoside-100), and 150 
ug/mL (Hyperoside-150); Concentration of Bravo: 10,000 
ug/mL (Bravo); Concentration of Maneb: 3,000 ug/mL 
(Maneb). Points and bars represent the means and standard 
errors of ?ve replicates. 
[0063] FIG. 6 is a graph illustrating the effect of different 
concentrations of CPT, trifolin, and hyperoside fungicides 
Bravo and Maneb on mycelial groWth of Fusarium avenu 
ceum. Concentrations of CPT: 10 ug/mL (CPT-10), 30 
ug/mL (CPT-30), 50 ug/mL (CPT-50), 70 ug/mL (CPT-70), 
100 ug/mL (CPT-100), 125 ug/mL (CPT-125), and 150 
ug/mL (CPT-150); Concentrations of Trifolin: 50 ug/mL 
(Trifolin-50), 100 ug/mL (Trifolin-100), and 150 ug/mL 
(Trifolin-150); Concentrations of Hyperoside: 50 ug/mL 
(Hyperoside-50), 100 ug/mL (Hyperoside-100), and 150 
ug/mL (Hyperoside-150); Concentration of Bravo: 10,000 
ug/mL (Bravo); Concentration of Maneb: 3,000 ug/mL 
(Maneb). Points and bars represent the means and standard 
errors of ?ve replicates. 
[0064] FIG. 7 is a graph illustrating the CPT concentra 
tions of different tissues at different ages in Camplolheca 
acuminala. 
[0065] FIG. 8 is a table illustrating the experimental 
concentrations of three compounds (CPT, trifolin, and 
hyperoside) isolated from Camplolheca leaves for in vitro 
tests against ?ve fungi isolated from Camplolheca acumi 
nala. 
[0066] FIG. 9 is a table illustrating the inhibition of 
alkaloid and ?avonoids isolated from Camplolheca against 
mycelial groWth of fungi. Note: Both EC5O (e?fective con 
centration that caused 50% inhibition of mycelial groWth) 
and MIC (the minimum inhibitory concentration) are the 
average of ?ve replicates measured When the fungus com 
pletely covered the agar surface under control conditions. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENT 
[0067] The present invention Will be described in relation 
to plant pathology, but may also have medical applications 
and be extended to use in the food industry. 
[0068] The present inventors have effected unprecedented 
antifungal activity through use of CPT, trifolin, and hypero 
side. Tests Were conducted against ?ve recently isolated 
fungi (molds) from C. acuminala. 
[0069] A. Extraction Procedures. 
[0070] Melting points Were measured With a MEL-TEMP 
capillary melting point apparatus and Were uncorrected. 
Optical rotations Were determined on a JASCO DIP-370 
digital polarimeter. UV and IR Were recorded on a HeWlett 
Packard 8435 spectrometer and an ATI Mattson Genesis 
Series FTIR spectrometer, respectively. NMR experiments 
Were performed on a Varian Unity Plus 600 MHZ spectrom 
eter and NMR data are reported as 6 (ppm) value, referenced 
to DMSO-d6. Silica gel (70-723 mesh, 60A, Aldrich) and 
RP Silica gel (RP-18, Aldrich) Were used for loW-pressure 
chromatography. TLC Was performed on silica gel 60 F254 
(Aldrich) using CHCl3/MeOH (9:1, solvent A and 4:1, 
Jun. 14, 2007 
solvent B), or reversed-phase C18 silica gel (Aldrich) using 
MeOH/H2O (70:30, solvent C and 30:70, solvent D). 
[0071] Leaves of C. acuminala Were collected, and air 
dried young leaf material (1000 g) Was ground to a coarse 
poWder and percolated With 95% EtOH ?ve times. Removal 
of the solvent under a vacuum at 600 C. yielded 50 g EtOH 
extract. The EtOH extract Was dissolved in MeOH/H2O 
(9: 1, 500 mL) and then partitioned successively With hexane 
(500 mL><5) and CHCl3 (500 mL><5) to produce a hexane 
extract (20.1 g), a CHCl3 extract (18.5 g), and a MeOH/H2O 
extract (12.1 g). Part of the CHCl3 extract (8.0 g) Was 
fractionated on a silica gel column (300 g) using CHCl3/ 
EtOAc (9:1 and 4:1, each 500 mL) and then CHCl3/MeOH 
(9: 1, 4:1, and 2:1, each 500 mL) to afford 50 fractions (each 
50 mL), Which Were combined to six fractions of A (30 mg, 
200-300 mL), B (18 mg, 800-900 mL), C (30 mg, 950-1050 
mL), D (230 mg, 1150-1250 mL), E (16 mg, 1350-1450 
mL), and F (6.7 g, 2100-2350 mL) on the basis oftheir TLC 
pro?les. Compound 1 (200 mg) Was precipitated from 
fraction D. Part of fraction F (2.0 g) Was refractionated on 
a silica gel column (200 g) using CHCl3/MeOH (9:1, 4:1, 
and 2:1, each 700 mL) to afford 40 fractions (each 50 mL). 
Compounds 2 (301 mg) and 3 (280 mg) Were precipitated 
from fractions 24-26 (1150-1300 mL) and fractions 29-30 
(1400-1500 mL), respectively. 
[0072] Camptothecin (4(S)-4-ethyl-4-hydroxy-1H 
pyrano-(3',4':6,7) indoliZino (1,2,-b) quinoline-3,14 (4H, 
12H)-dione) (Compound 1) Was obtained as a yelloWish 
amorphous solid: mp. 265-2660 C. (CHCl3); [0t]D25-56.5o 
(c 0.1, DMSO); Rf 0.72 (silica gel, solvent A) and 0.63 
(reversed-phase C18 silica gel, solvent C); UV (EtOH) 
kmax (log 6) 218 (4.38), 262 (4.13), 330 (2.87), 370 (3.98), 
380 (4.05) nm; IR vmax (KBr) 3201, 1756, 1663, 1596 
cm-1; 1H NMR (DMSO-d6, 600 MHZ) 6 8.69 (1H, s, H-7), 
8.16 (1H, d, J=7.8 HZ, H-12), 8.11 (1H, d, J=7.8 HZ, H-9), 
7.86 (1H, t, J=7.8 HZ, H-11), 7.70 (1H, t, J=7.8 HZ, H-10), 
7.37 (1H, s, H-14), 5.42 (2H, s, H-17), 5.29 (2H, s, H-5), 
1.86 (2H, q, J=7.2 HZ, H-19), 0.88 (3H, t, J=7.2 HZ, H-18); 
13C NMR (DMSO-d6, 150 MHZ) 6 173.6 (C, C-21), 157.6 
(C, C-22), 153.5 (C, C-2), 150.1 (C, C-15), 148.1 (C, C-13), 
145.9 (C, C-3), 131.5 (CH, C-7), 130.6 (C, C-6), 130.2 (CH, 
C-11), 129.2 (CH, C-12), 128.7 (CH, C-9), 128.1 (C, C-8), 
127.8 (CH, C-10), 120.1 (C, C-16), 96.9 (CH, C-14), 73.6 
(C, C-20), 65.6 (CH2, C-17), 50.8 (CH2, C-5), 30.2 (CH2, 
C-19), 7.8 (CH3, C-18). 
[0073] Trifolin (kaempferol-3-O-[3-D-galactopyranoside) 
(Compound 2) Was obtained as a yelloWish amorphous 
solid: [0t]D25-78.6o (c 0.1, DMSO); Rf 0.51 (silica gel, 
solvent B) and 0.60 (reversed-phase C18 silica gel, solvent 
D); UV (EtOH) kmax (log 6) 265 (4.21), 355 (3.52) nm; IR 
vmax (KBr) 3356, 3000, 1651, 1610, 1573 cm-1; 1H NMR 
(DMSO-d6, 600 MHZ) 6 12.6 (1H, s, OH-5), 8.03 (2H, d, 
J=9.0 HZ, H-2', H-6'), 6.87 (2H, d, J=9.0 HZ, H-3', H-540 ), 
6.43 (1H, d, J=2.5 HZ, H-8), 6.20 (1H, d, J=2.5 HZ, H-6), 
5.46 (1H, d, J=7.5 HZ, H-1"), 3.58 (1H, m, H-6"a), 3.56 (1H, 
m, H-6"b), 3.38 (1H, m, H-5"), 3.32 (1H, m, H-2"), 3.22 
(1H, m, H-3"), 3.12 (1H, m, H-4'); 13C NMR (DMSO-d6, 
150 MHZ) 6 177.5 (C, C-4), 164.1 (C, C-7), 161.2 (C, C-5), 
159.9 (C, C-4'), 156.4 (C, C-9), 156.2 (C, C-2), 133.2 (C, 
C-3), 130.2 (CH, C-2', C-6'), 115.7 (CH, C-3', C-5'), 114.5 
(C, C-1'), 104.0 (C, C-10), 101.5 (CH, C-1"), 99.1 (CH, 
C-6), 94.0 (CH, C-8), 77.0 (CH, C-5"), 74.8 (CH, C-3"), 
73.6 (CH, C-2"), 70.5 (CH, C-4"), 61.9 (CH2, C-6"). 
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[0074] Hyperoside (quercetin-3-O-[3-D-galactopyrano 
side) (Compound 3) Was obtained as a yellowish amorphous 
solid: [0t]D25-81.8o (c 0.1, DMSO); Rf 0.34 (silica gel, 
solvent B) and 0.75 (reversed-phase C18 silica gel, solvent 
D); UV (EtOH) kmax (log 6) 256 (4.37), 356 (3.58) nm; IR 
vmax (KBr) 3360, 3031, 1652, 1615, 1569 cm-1; 1H NMR 
(DMSO-d6, 600 MHZ) 6 12.6 (1H, s, OH-5), 7.66 (1H, d, 
J=7.8 HZ, H-6'), 7.53 (1H, br s, H-2'), 6.80 (1H, d, J=7.8 HZ, 
H-5'), 6.40 (1H, d, J=2.0 HZ, H-8), 6.20 (1H, d, J=2.0 HZ, 
H-6), 5.37 (1H, d, J=7.2 HZ, H-1"), 3.65 (1H, m, H-6"a), 
3.57 (1H, m, H-6"b), 3.44 (1H, m, H-5"), 3.36 (1H, m, 
H-2"), 3.33 (1H, m, H-3"), 3.16 (1H, m, H-4"); 13C NMR 
13C NMR (DMSO-d6, 150 MHZ) 6 177.8 (C, C-4), 164.3 
(C, C-7), 161.3 (C, C-5), 156.5 (C, C-9), 156.3 (C, C-2), 
148.7 (C, C-4'), 144.5 (C, C-3'), 133.8 (C, C-3), 122.0 (CH, 
C-6'), 121.5 (C, C-1'), 116.0 (CH, C-2'), 115.1 (CH, C-5'), 
103.9 (C, C-10), 101.3 (CH, C-1"), 98.9 (CH, C-6), 94.0 
(CH, C-8), 77.3 (CH, C-5"), 74.6 (CH, C-3"), 73.5 (CH, 
C-2"), 70.3 (CH, C-4"), 61.5 (CH2, C-6"). 
[0075] B. Fungal Inhibition Experimentation. 
[0076] Allernaria allernala, Epicoccum nigrum, Peslalo 
Zia guepinii, Drechslera sp., and Fusarium avenaceum Were 
isolated from infected leaves and roots of C. acuminala. The 
strains Were cultured and maintained on potato dextrose agar 
(PDA) medium. 
[0077] CPT, trifolin, and hyperoside (isolated from Camp 
Zolheca as above) Were tested for their ability to inhibit these 
fungi, as compard With tWo classical fungicides, Bravo 
(active ingredient: chlorothalonil) and Maneb (active ingre 
dient: manganous ethylenebis [dithiocarbamate]), as refer 
ences. The concentrations of the conventional fungicides 
Were those recommended by the manufacturers (Bravo: 
10,000 ug/mL; Maneb: 3,000 ug/mL). 
[0078] In addition to a negative control (0) and tWo 
fungicides as positive controls for each of the ?ve isolated 
pathogens, seven levels of CPT Were tested With each of the 
fungi and three levels of trifolin and hyperoside Were tested 
With R guepinii, Drechslera sp. and F avenaceum, respec 
tively (see FIG. 8). 
[0079] Trifolin and hyperoside treatments Were applied at 
concentrations of 50, 100, and 150 ug/mL, respectively. For 
all cultures, ?nal concentrations Were made in molten (500 
C.) potato dextrose agar (Difco), and 10 mL aliquots Were 
poured into Petri dishes (85 mm in diameter). Within 24 
hours after pouring, each of the plates Was inoculated With 
one of the ?ve fungi. One 5><5 mm mycelial plug Was cut 
from the actively groWing front of a 2 Week old colony, then 
placed With the inoculum side doWn in the center of each 
treatment plate. The cultures Were incubated at 240 C. For all 
experiments, ?ve replicate plates Were inoculated for each 
treatment. 
[0080] Mycelial groWth on each plate Was observed daily 
and recorded on a transparent ?lm for the ?rst tWo Weeks, 
then recorded on the 16th, 20th, 23rd, and 28th days. Colony 
radii Were measured along four vertical radial directions. 
The mean of the four measurements Was calculated as the 
groWth rate on each plate. Mean and standard error Were 
calculated from the ?ve replicates of each treatment. For 
each of the fungi, values of EC5O (effective concentration 
that caused 50% inhibition of mycelial groWth) and MIC 
(the minimum inhibitory concentration) of each compound 
Were estimated. 
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[0081] C. Findings. 
[0082] 
[0083] CPT signi?cantly inhibited Allernaria groWth at 
the loWest treatment concentration of 10 ug/mL (CPT-10) 
(p<0.001). Colonies exposed to CPT-10 Were inhibited by 
41-66%. It took 23 days for mycelium under the CPT-10 
treatment to completely cover the agar surface, as compared 
to 13 days under control treatment. CPT-25 (CPT at the 
concentration of 25 ug/mL) Was similar to Bravo in its 
ability to inhibit A. allernala (FIG. 2). Colonies in both 
treatments started to groW on the second day of the experi 
ment and their radii Were alWays Within about one millime 
ter of one another. CPT-25 colony expansion Was reduced by 
215% (28 days to cover the agar surface vs. 13 days for 
control). On day 13, colonies in the CPT-25 treatment Were 
52.8% smaller than controls. Thus, it is estimated that the 
EC50 of CPT for A. allernala is less than 25 ug/mL. The 
CPT-50 treatment Was able to inhibit fungal groWth by more 
than 180%. The fungus Was totally controlled by CPT at 
concentrations of 75 ug/mL (CPT-75) and above, and by the 
fungicide Maneb. 
1. Antifungal Activity against Allernaria allernala. 
[0084] 2. Antifungal Activity against Epicoccum nigrum. 
[0085] Epicoccum nigrum greW faster than A. allernala 
under control conditions in the experiment, With colonies 
covering the agar surface in 10 days (FIG. 3). HoWever, this 
fungus Was more strongly inhibited by CPT and fungicide 
than A. allernala. CPT at loW levels (10 ug/mL and 25 
ug/mL) delayed mycelial groWth of E. nigrum by 280% (28 
days to cover agar surface vs. 10 days for control). CPT-10 
and CPT-25 treatments Were not signi?cantly different in 
their ability to inhibit E. nigrum. On day 10, colonies in the 
CPT-10 treatment Were 65% smaller than controls. Thus, the 
EC5O of CPT for E. nigrum is estimated to be less than 10 
ug/mL. Similarly to results With A. allernala, CPT-50 (CPT 
at the concentration of 50 ug/mL) inhibited groWth of E. 
nigrum by more than 90% While CPT-75 (CPT at the 
concentration of 75 ug/mL) and higher concentrations as 
Well as Maneb totally inhibited groWth. Bravo treatment Was 
slightly superior to CPT-10 and CPT-25. Colonies exposed 
to Bravo did not start to groW until the ?fth day; by day 15 
they had radii of 13 mm compared to 20 mm in CPT-25 
treatment. The CPT-50 treatment Was superior to Bravo. 
Under this treatment, groWth did not begin until the 8th day 
of the experiment. On day 20, colony radii measured 19 mm 
under Bravo treatment but only 8 mm When exposed to 
CPT-50. 
[0086] 3. Antifungal Activity against Peslalolia guepinii. 
[0087] Peslalolia guepinii shoWed a similar groWth pat 
tern to E. nigrum under control conditions (FIG. 4). CPT-10 
reduced mycelial groWth by 43.5% on the 11th day When the 
fungus under control treatment had covered the agar surface. 
Colonies exposed to CPT-10 treatment did not reach the 
petri dish margins until day 20. Thus, it is estimated that the 
EC5O of CPT for R guepinii is approximately 10 ug/mL. 
HoWever, CPT totally inhibited groWth only at levels of 125 
ug/mL and above. Both fungicides also successfully con 
trolled P. guepinii. Trifolin and hyperoside Were similar in 
their ability to inhibit R guepinii. On day 11, colonies 
exposed to either trifolin-50 or hyperoside-50 Were inhibited 
by 53.4% and 53.8%, respectively. The EC5O of both ?a 
vonoids for R guepinii is estimated to be approximately 50 
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ug/mL. However, as concentrations increased to 100 ug/mL, 
the ?avonoids Were more e?‘ective in inhibition of R gue 
pinii than CPT; MICs of both trifolin and hyperoside for R 
guepinii are most likely below 125 ug/mL, the level at Which 
CPT successfully controlled the fungus. 
[0088] 4. Antifungal Activity against Drechslera sp. 
[0089] Drechslera sp. greW more sloWly thanA. allernala, 
E. nigrum, and R guepinii under control conditions but Was 
also more sensitive to CPT, ?avonoids, and fungicides than 
the other fungi tested (FIG. 5). CPT at all experimental 
levels shoWed greater inhibition rates than Bravo. This 
fungicide reduced mycelial groWth by 54.4% on day 20, 
When control mycelium completely covered the agar sur 
face. Thus, the EC5O of CPT for Drechslera is less than 10 
ug/mL. HoWever, CPT only completely inhibited fungal 
groWth at the concentrations of 100 ug/mL and higher. 
Trifolin-50 and hyperoside-50 (trifolin and hyperoside at the 
concentrations of 50 ug/mL) Were similar in their ability to 
inhibit Drechslera. On day 20, colonies exposed to either 
trifolin-50 or hyperoside-50 Were inhibited by 76.1% and 
74.3%, respectively. Thus, the EC5O values of both ?a 
vonoids against Drechslera are less than 50 ug/mL. Hypero 
side-100 (hyperoside at the concentration of 100 ug/mL) 
inhibited fungal groWth successfully With little groWth by 
day 28, While trifolin-100 (trifolin at the concentration of 
100 ug/mL) totally controlled the fungus over the course of 
the entire experiment. CPT at the concentrations of 100 
ug/mL and above, trifolin at the concentrations of 100 and 
150 ug/mL, hyperoside at the concentrations of 150 ug/mL, 
and Maneb completely inhibited groWth of Drechslera. 
[0090] 5. Antifungal Activity against Fusarium avenu 
ceum. 
[0091] Fusarium avenaceum exhibited the sloWest groWth 
rate of all experimental fungi under control conditions, but 
Was someWhat less sensitive to CPT, ?avonoids, and fungi 
cides (FIG. 6). Bravo shoWed e?‘ective inhibition of myce 
lial groWth during the ?rst several days of the experiment but 
Was less e?fective in the later stages. On day 28, mycelium 
With Bravo treatment completely covered the agar surface 
similar to the control colonies. CPT-10 Was much more 
e?‘ective than Bravo, With 70-80% inhibition of mycelial 
groWth during the ?rst several days of the experiment and 
approximately 40% inhibition in the later stages. CPT-30 
inhibited the rate of mycelial groWth by more than 60%. 
Thus, the EC5O of CPT for F avenaceum is estimated to be 
betWeen 10 and 30 ug/mL. 
[0092] Higher levels of CPT more e?cectively inhibited 
mycelial groWth but complete inhibition Was not achieved 
until the concentration of 125 ug/mL. Trifolin and hypero 
side exhibited similar inhibition patterns at the level of 100 
ug/mL, but trifolin Was more e?‘ective than hyperoside at the 
concentration of 50 ug/mL. Trifolin-50 and hyperoside-50 
Were less e?‘ective against E avenaceum than Bravo and 
CPT-10 at the beginning of experiment but more effective 
than Bravo and similar to CPT-10 during the later stages of 
the experiment. On day 28, trifolin and hyperoside inhibited 
fungal groWth by 35.8% and 31.6%, respectively, at the 
concentration of 50 ug/mL, and by 74.8% and 72.6%, 
respectively, at the concentration of 100 ug/mL. 
[0093] Thus, it is estimated that EC5O values of both 
?avonoids against E avenaceum are betWeen 50 and 100 
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ug/mL. Hyperoside at the concentration of 150 ug/mL 
completely inhibited fungal groWth during the ?rst four 
Weeks, While trifolin at the same level totally controlled the 
fungus during the entire experiment. CPT at the concentra 
tions of 125 and 150 ug/mL and Maneb also completely 
inhibited groWth of F avenaceum. 
[0094] Use of the agents camptothecin, trifolin and/or 
hyperoside in inhibiting initial fungal infestation, containing 
existing infestation, or reversing existing infestation can 
take many forms. These may include foliar sprays, soil 
drench applications, treatment of plant groWth medium 
(before or after plants are resident therein), and, in the case 
of trees, injection into trunks or branches. The method of the 
present invention is not limited to any particular form, nor 
need it be in terms of novelty or obviousness, in vieW of the 
completely unanticipated use of the cited compounds in the 
context of anti-fungal measures, despite the compelling need 
therefore. 
[0095] Although the invention has been described With 
reference to speci?c embodiments, this description is not 
meant to be construed in a limited sense. Various modi?ca 
tions of the disclosed embodiments, as Well as alternative 
embodiments of the inventions Will become apparent to 
persons skilled in the art upon the reference to the descrip 
tion of the invention. 
[0096] It is, therefore, contemplated that the appended 
claims Will cover such modi?cations that fall Within the 
scope of the invention. 
1 claim: 
1. A method for preventing or inhibiting the groWth of 
fungal pathogens in plants comprising the steps of: 
selecting one or more plant extracts from a group con 
sisting of camptothecin, trifolin and hyperoside; and 
applying said one or more plant extracts to a plant. 
2. The method of claim 1 further comprising the step of, 
before said selecting one or more plant extracts, of extract 
ing said one or more extracts from one or more plants. 
3. The method of claim 2 Wherein said one or more plants 
comprises plants selected from a groups consisting of: 
A. Plants from Camplolheca (Nyssaceae), comprising 
Camplolheca acuminala Decaisne, Camplolheca 
acuminala var. Zenuifolia Fang et Song, Camplolheca 
acuminala var. rolundifolia Yang et Duan, Camplolh 
eca yunnanensis Dode, Camplolheca lowreyana Li, 
Camplolheca lowreyana Li ‘Katie’, Camplolheca low 
reyana Li ‘Hicksii’; 
B. Ervalamia (Apocynaceae); 
C. Nolhapodyles (Mappia) (Olacaceae); 
D. Ophiorrhiza (Rubiaceae); 
E. Merrilliodendron (lcacinaceae); 
F. Mosluea (Loganiaceae); and 
G. Pyrenacanlha (lcacinaceae). 
4. The method of claim 2 Wherein said one or more plants 
is the member of the Nyssaceae family knoWn as the 
Camplolheca acuminala tree. 
5. A method for preventing or inhibiting the groWth of 
fungal pathogens in plants comprising the steps of: 
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selecting a ?rst measure of trifolin; and 
applying said ?rst measure of trifolin to a plant. 
6. The method of claim 5 further comprising the step of, 
before said selecting said ?rst measure of trifolin, of extract 
ing said trifolin from one or more plants. 
7. A method for preventing or inhibiting the groWth of 
fungal pathogens in plants comprising the steps of: 
selecting a ?rst measure of hyperoside; and 
applying said ?rst measure of hyperoside to a plant. 
8. The method of claim 7 further comprising the step of, 
before said selecting said ?rst measure of hyperoside, of 
extracting said hyperoside from one or more plants. 
9. A method for preventing or inhibiting the groWth of 
fungal pathogens in plants comprising the steps of: 
selecting a ?rst measure of camptothecin; and 
applying said ?rst measure of camptothecin to a plant. 
10. The method of claim 9 further comprising the step of, 
before said selecting said ?rst measure of camptothecin, of 
extracting said camptothecin from one or more plants 
selected from a group consisting of: 
A. Plants from Camplolheca (Nyssaceae), comprising 
Camplolheca acuminala Decaisne, Camplolheca 
acuminala var. Zenuifolia Fang et Song, Camplolheca 
acuminala var. rolundifolia Yang et Duan, Camplolh 
eca yunnanensis Dode, Camplolheca lowreyana Li, 
Camplolheca lowreyana Li ‘Katie’, Camplolheca low 
reyana Li ‘Hicksii’; 
B. Ervalamia (Apocynaceae); 
C. Nolhapodyles (Mappia) (Olacaceae); 
D. Ophiorrhiza (Rubiaceae); 
E. Merrilliodendron (lcacinaceae); 
F. Mosluea (Loganiaceae); and 
G. Pyrenacanlha (lcacinaceae). 
11. A method for preventing or inhibiting the groWth of 
fungal pathogens in plants comprising the steps of: 
selecting one or more plant extracts from a group con 
sisting of camptothecin trifolin and hyperoside; and 
applying said one or more plant extracts to a plant groWth 
medium. 
12. The method of claim 11 further comprising the step of, 
before said selecting one or more plant extracts, of extract 
ing said one or more extracts from one or more plants. 
13. A method for preventing or inhibiting the groWth of 
fungal pathogens in plants comprising the steps of: 
selecting a ?rst measure of trifolin; and 
applying said ?rst measure of trifolin to a plant groWth 
medium. 
14. The method of claim 13 further comprising the step of, 
before said selecting said ?rst measure of trifolin, of extract 
ing said trifolin from one or more plants. 
15. A method for preventing or inhibiting the groWth of 
fungal pathogens in plants comprising the steps of: 
selecting a ?rst measure of hyperoside; and 
applying said ?rst measure of hyperoside to a plant 
groWth medium. 
16. The method of claim 15 further comprising the step of, 
before said selecting said ?rst measure of hyperoside, of 
extracting said hyperoside from one or more plants. 
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17. A method for preventing or inhibiting the groWth of 
fungal pathogens in plants comprising the steps of: 
selecting a ?rst measure of camptothecin; and 
applying said ?rst measure of camptothecin to a plant 
groWth medium. 
18. The method of claim 17 further comprising the step of, 
before said selecting said ?rst measure of camptothecin, of 
extracting said camptothecin from one or more plants. 
19. The method of claim 18 Wherein said one or more 
plants comprises plants selected from a groups consisting of: 
A. Plants from Camplolheca (Nyssaceae), comprising 
Camplolheca acuminala Decaisne, Camplolheca 
acuminala var. Zenuifolia Fang et Song, Camplolheca 
acuminala var. rolundifolia Yang et Duan, Camplolh 
eca yunnanensis Dode, Camplolheca lowreyana Li, 
Camplolheca lowreyana Li ‘Katie’, Camplolheca low 
reyana Li ‘Hicksii’; 
B. Ervalamia (Apocynaceae); 
C. Nolhapodyles (Mappia) (Olacaceae); 
D. Ophiorrhiza (Rubiaceae); 
E. Merrilliodendron (lcacinaceae); 
F. Mosluea (Loganiaceae); and 
G. Pyrenacanlha (lcacinaceae). 
20. The method of claim 18 Wherein said one or more 
plants is the member of the Nyssaceae family knoWn as the 
Camplolheca acuminala tree. 
21. A method for preventing or inhibiting the groWth of 
molds in a substrate comprising the steps of: 
selecting one or more plant extracts from a group con 
sisting of camptothecin, trifolin, and hyperoside; and 
applying said one or more plant extracts to said substrate. 
22. The method of claim 21 further comprising the step of, 
before said selecting one or more plant extracts, of extract 
ing said one or more extracts from one or more plants. 
23. The method of claim 22 Wherein said one or more 
plants comprises plants selected from a groups consisting of: 
A. Plants from Camplolheca (Nyssaceae), comprising 
Camplolheca acuminala Decaisne, Camplolheca 
acuminala var. Zenuifolia Fang et Song, Camplolheca 
acuminala var. rolundifolia Yang et Duan, Camplolh 
eca yunnanensis Dode, Camplolheca lowreyana Li, 
Camplolheca lowreyana Li ‘Katie’, Camplolheca low 
reyana Li ‘Hicksii’; 
B. Ervalamia (Apocynaceae); 
C. Nolhapodyles (Mappia) (Olacaceae); 
D. Ophiorrhiza (Rubiaceae); 
E. Merrilliodendron (lcacinaceae); 
F. Mosluea (Loganiaceae); and 
G. Pyrenacanlha (lcacinaceae). 
24. The method of claim 22 Wherein said member of the 
Nyssaceae family is the Camplolheca acuminala tree. 
